In light of the potential use of the thiazolidinedione family of peroxisome proliferator-activated receptor-␥ (PPAR␥) agonists in prostate cancer treatment, this study assessed the mechanism by which these agents suppress prostate-specific antigen (PSA) secretion in prostate cancer cells. Two lines of evidence indicate that the effect of thiazolidinediones on PSA downregulation is independent of PPAR␥ activation. First, this thiazolidinedione-mediated PSA down-regulation is structure-specific irrespective of the relative PPAR␥ agonist potency. Second, the PPAR␥-inactive analogs of troglitazone and ciglitazone [⌬2TG (5-[4-(6-hydroxy-2,5,7,8-tetramethyl-chroman-2-yl-methoxy)-benzylidene]-thiazolidine-2,4-dione) and ⌬2CG (5-[4-(1-methyl-cyclohexylmethoxy)-benzylidene]-thiazolidine-2,4-dione), respectively] exhibit higher potency than the parent compound in inhibiting dihydrotestosterone (DHT)-stimulated PSA secretion. Although 10 M troglitazone and ⌬2TG significantly inhibit PSA secretion, they do not alter the expression level of androgen receptor (AR) or interfere with DHT-activated nuclear translocation of AR. However, reporter gene and chromatin immunoprecipitation studies indicate that troglitazone and ⌬2TG block AR recruitment to the androgen response elements within the PSA promoter. Thus, this study raises the question of whether the ability of oral troglitazone to reduce PSA levels in prostate cancer patients is therapeutically relevant. A major concern is that the concentration for troglitazone to mediate antitumor effects is severalfold higher than that of PSA down-regulation, which is difficult to attain at therapeutic doses. Nevertheless, it is noteworthy that troglitazone and ⌬2TG at high doses were able to inhibit AR expression. From a translational perspective, separation of PPAR␥ agonist activity from AR down-regulation provides a molecular basis to use troglitazone as a platform to design AR-ablative agents.
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Becauase prostate-specific antigen (PSA) is used as a surrogate marker for disease progression and response for prostate cancer treatments (for review, see Polascik et al., 1999) , the effect of therapeutic agents on PSA expression warrants attention (for review, see Dixon et al., 2001) . Because PSA expression and cell proliferation are independently regulated functions in prostate cancer cells (Cunha et al., 1987) , a therapeutic agent may down-regulate PSA expression/secretion without inhibiting tumor cell growth. In such a case, a patient receiving this agent might be falsely considered to have a clinical response. Among a series of agents examined to date, the ability of thiazolidinediones (e.g., troglitazone) to down-regulate PSA is noteworthy (Hisatake et al., 2000; Mueller et al., 2000) . This family of peroxisome proliferatoractivated receptor ␥ (PPAR␥) agonists increases transcription of certain insulin-sensitive genes involved in the metabolism and transport of lipids through PPAR␥ activation, thereby improving insulin sensitivity. Moreover, at high doses, these agents exhibit in vitro and in vivo antitumor effects against human prostate cancer (Kubota et al., 1998; Mueller et al., 2000; Kumagai et al., 2004) , although the underlying mechanism remains elusive. In light of the role of PPAR␥ in the regulation of prostatic epithelial proliferation and differentiation, thiazolidinediones have been suggested to be useful in the setting of adjuvant and chemopreventive treatments of prostate cancer (Lieberman, 2002; Koeffler, 2003; Jiang et al., 2004) . More recently, accumulating evidence suggests that the effect of thiazolidinediones on cell cycle and apoptosis in cancer cells is dissociated from their PPAR␥ agonist activity (Sugimura et al., 1999; Motomura et al., 2000; Okura et al., 2000; Gouni-Berthold et al., 2001; Palakurthi et al., 2001; Takeda et al., 2001; Bae and Song, 2003; Baek et al., 2003; Huang et al., 2005; Shiau et al., 2005) . For example, there is discrepancy of 3 orders of magnitude between the concentration required to produce antitumor effects and that required to mediate PPAR␥ activation. In addition, the antitumor effect seems to be structure-specific, irrespective of potency in PPAR␥ activation (i.e., troglitazone and ciglitazone are active, whereas rosiglitazone and pioglitazone are not). More recently, we demonstrated that the effect of thiazolidinediones on apoptosis and cell cycle arrest in cancer cells was attributable, in part, to their ability to inhibit Bcl-xL/Bcl-2 functions and to ablate cyclin D1 expression Shiau et al., 2005) .
Considering the potential use of these agents in inhibiting prostate carcinogenesis, the mechanism whereby these PPAR␥ agonists repress PSA expression warrants investigation. By using PPAR␥-inactive thiazolidinedione derivatives, we obtained evidence that the effect of troglitazone and ciglitazone on PSA down-regulation was independent of PPAR␥ activation. Moreover, the ability of low doses (Յ10 M) of troglitazone and ciglitazone to suppress PSA expression was caused not by reduced AR expression but by a decrease in the AR response element (ARE) activity in the PSA promoter.
Materials and Methods
Reagents. Troglitazone and ciglitazone were purchased from Sigma (St. Louis, MO) and Cayman Chemical (Ann Arbor, MI), respectively. Rosiglitazone and pioglitazone were prepared from the respective commercial capsules by solvent extraction followed by recrystallization or chromatographic purification. 5, 7, 
, and ⌬2PG (5-{4-[2-(5-ethyl-pyridin-2-yl)-ethoxy]-benzylidene}-thiazolidine-2,4-dione) are thiazolidinedione derivatives with attenuated or unappreciable activity in PPAR␥ activation Shiau et al., 2005) . These agents were dissolved at various concentrations in DMSO and were added to cells in medium with a final DMSO concentration of 0.1%. Dihydrotestosterone (DHT; Sigma, St. Louis, MO) was dissolved in 100% ethanol (8 mg/ml) as a stock solution for serial dilutions in water. Mouse antibodies against AR, PSA, and ␣-tubulin were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Goat anti-rabbit and rabbit anti-mouse immunoglobulin G horseradish peroxidase conjugates were from Jackson ImmunoResearch Laboratories (West Grove, PA).
Cell Culture. LNCaP and 22RV1 cells were purchased from the American Type Culture Collection (Manassas, VA). LNCaP cells were cultured in a T-75 flask with RPMI 1640 medium containing 10% heat-inactivated FBS at 37°C in a humidified incubator containing 5% CO 2 ; 22RV1 cells were cultured in the same media supplemented with 4.5 mg/ml of glucose. For individual experiments, 10% FBS-supplemented RPMI 1640 medium was replaced by phenol redfree RPMI 1640 medium containing 10% charcoal/dextran-stripped FBS. The cells were cultured for 2 days before drug treatments.
PSA Immunoassay. Quantitative determinations of PSA in culture medium were performed by using a human PSA enzyme-linked immunosorbent assay kit (Anogen, Mississauga, ON, Canada). In brief, LNCaP and 22RV1 cells were plated in 96-well plates (6000 cells/well) in phenol red-free RPMI 1640 medium with 10% charcoal/ dextran-stripped FBS without and with glucose, respectively, incubated for 48 h, and treated with the test agent at the indicated concentrations in the same medium in six replicates. Control cells received dimethyl sulfoxide vehicle at a concentration equal to that of drug-treated cells. At different time intervals, 20 l of the cultured medium was collected, diluted 10-fold with the sample diluent, and the amount of PSA was determined by following the manufacturer's instructions. Absorbance at 450 nm was determined on a microtiter plate reader.
Transfections and Luciferase Assay. The 6.0-kilobase PSApromoter-linked reporter plasmid PSA6.0-Luc and the human AR expression construct pCMVhAR were provided by Dr. Chawnshang Chang (University of Rochester Medical Center, Rochester, NY) and Dr. James Dalton (The Ohio State University, Columbus, OH), respectively. The PPRE-x3-TK-Luc reporter vector contains three copies of the PPAR-response element (PPRE) upstream of the thymidine kinase promoter-luciferase fusion gene and was kindly provided by Dr. Bruce Spiegelman (Harvard University, Cambridge, MA). LNCaP or DU145 cells were incubated in phenol red-free RPMI 1640 medium with 10% FBS until they reached 50 to 70% confluence on a 100-mm plate and were transfected with 6 g of each of the aforementioned plasmids using Fugene 6 (Roche, Indianapolis, IN) in RPMI 1640 medium. For each transfection, herpes simplex virus thymidine kinase (TK) promoter-driven Renilla reniformis luciferase was used as an internal control for normalization. After transfections, cells were incubated in 10% charcoal-stripped FBS and RPMI 1640 medium, subject to different treatments for the times indicated in Figs. 1 and 6 and collected with passive lysis buffer (Promega, Madison, WI). Luciferase activity in the cell lysates was determined by luminometry. All transfection experiments were carried out in triplicate wells and repeated separately at least three times.
Immunoblotting. Cells in T-75 flasks were collected by scraping and suspended in 60 l of phosphate-buffered saline (PBS). Two microliters of the suspension was taken for protein analysis using the Bradford assay kit (Bio-Rad, Hercules, CA). To the remaining solution was added the same volume of 2ϫ SDS-polyacrylamide gel electrophoresis sample loading buffer (100 mM Tris-HCl, pH 6.8, 4% SDS, 5% ␤-mercaptoethanol, 20% glycerol, and 0.1% bromphenol blue). The mixture was sonicated briefly and then boiled for 5 min. Equal amounts of proteins were loaded onto 10% SDS-polyacrylamide gel electrophoresis gels.
After electrophoresis, protein bands were transferred to nitrocellulose membranes in a semidry transfer cell. The transblotted membrane was washed twice with Tris-buffered saline containing 0.1% Tween 20 (TBST). After blocking with TBST containing 5% nonfat milk for 40 min, the membrane was incubated with the appropriate primary antibody in TBST-1% nonfat milk at 4°C overnight. All primary antibodies were diluted 1:1000 in 1% nonfat milk-containing TBST. After treatment with the primary antibody, the membrane was washed three times with TBST for a total of 15 min, followed by incubation with goat anti-rabbit or anti-mouse IgG-horseradish peroxidase conjugates (diluted 1:5000) for 1 h at room temperature and three washes with TBST for a total of 1 h. The immunoblots were visualized by enhanced chemiluminescence.
Immunocytochemical Analysis of DHA-Stimulated AR Nuclear Localization. LNCaP cells were cultured on slides in six-well plates (200,000 cells/well) in 10% charcoal-stripped, FBS-supplemented phenol red-free RPMI 1640 and exposed to 10 nM DHT, 10 nM DHT plus 10 M troglitazone, or ⌬2TG for 48 h, washed with Dulbecco's PBS, fixed with 4% paraformaldehyde for 30 min at 37°C, and then washed with PBS twice. For staining of AR, the cells were permeabilized with 0.1% Triton X-100 in 1% FBS-containing PBS and treated with mouse monoclonal anti-AR (1:100 dilution) in PBS molpharm.aspetjournals.org containing 0.1% Triton X-100 and 0.2% bovine serum albumin at 4°C overnight and washed with PBS. For fluorescent microscopy, Alexa Fluor 488 goat anti-mouse IgG (1:200 dilution; Molecular Probes) was used for conjugating AR. The nuclear counterstaining was performed using a 4,6-diamidino-2-phenylindole-containing mounting medium (Vector Laboratories, Burlingame, CA) before examination. Images of immunocytochemically labeled samples were observed using a Nikon microscope (Eclipse E800) with an argon laser and a helium-neon, and appropriate filters (excitation wavelengths, 488 nm for AR and 543 nm for 4,6-diamidino-2-phenylindole).
Chromatin Immunoprecipitation. ChIP was performed by using an EZ-Chip kit (Upstate Biotechnology, Inc., Lake Placid, NY) according to the manufacturer's instructions. LNCaP cells were cultured in 10 ml of 10% charcoal/dextran stripped, FBS-supplemented phenol red-free RPMI 1640 medium for 48 h. After drug treatment for 12 h, cells were cross-linked with 10 ml of fresh medium containing 1% formaldehyde at room temperature for 10 min. Glycine solution (1 ml, 1.25 M) was added to stop the cross-linking reaction, and cells were washed twice with 5 ml of PBS. The cells were collected, suspended in 350 l of SDS lysis buffer, sonicated on wet ice by using a Virtis model Sonic 300 sonicator with five sets of 10-s pulses and 8% of max power, and centrifuged at 15,000g at 4°C for 10 min. Supernatants were collected, diluted with the dilution buffer, and treated with protein G agarose at 4°C for 1 h to preclean the chromatin. After a brief centrifugation at 4000g, the supernatant was collected into a fresh 1.5-ml microcentrifuge tube. Ten microliters of the supernatant was stored away at 4°C to be used as input, and the remaining supernatant was incubated with anti-AR (Upstate Biotechnology) at 4°C overnight. After immunoprecipitation, the solution was treated with 60 l of protein G agarose slurry at 4°C for 1 h, followed by a brief centrifuge at 4000g. The protein G beads were washed, 1 ml each in tandem, with ice-cold low-salt wash buffer, high-salt wash buffer, LiCl wash buffer, and Tris/EDTA buffer, followed by extraction with elution buffer twice. The eluted solution was added 8 l of 5 M NaCl and incubated at 65°C overnight. A spin column provided in the kit was used to purify DNA fragments. For PCR analysis, 1 l of input DNA extraction and 5 l of immunoprecipitated DNA extraction were used for 36 cycles of amplification. The primers for androgen response element (ARE)I (A/B), AREII (C/D), and the middle region (E/F) (Shang et al., 2002) were obtained from Integrated DNA Technologies (Coralville, IA). The sequences were as follows: A, TCTGCCTTTGTCCCCTAGAT; B, AACCTTCAT-TCCCCAGGACT; C, AGGGATCAGGGAGTCTCACA; D, GCTAG-CACTTGCTGTTCTGC; E, CTGTGCTTGGAGTTTACCTGA; F, GCAGAGGTTGCAGTGAGCC.
Results

PPAR␥-Independent Repression of PSA Secretion and Expression in LNCaP Cells.
We have developed PPAR␥-inactive thiazolidinediones by introducing a double bond adjoining the terminal thiazolidine-2,4-dione ring (Fig.  1A) . Two lines of evidence indicate that this structural modification abrogated the PPAR activity. First, these ⌬2 analogs (⌬2TG, ⌬2RG, ⌬2PG, and ⌬2CG) were inactive in PPAR␥ activation according to a PPAR␥ transcription factor enzymelinked immunosorbent assay . Second, LNCaP and DU-145 cells were transfected with a reporter construct (PPRE-X3-TK-Luc) that contains three copies of PPRE upstream of the luciferase gene and then tested for PPAR␥ transactivation. Although LNCaP cells transfected with PPRE-X3-TK-Luc did not respond to any the four thiazolidinedione-PPAR␥ agonists regarding luciferase induction, the transfected DU-145 cells exhibited differential increase in luciferase activity in response to these agents (10 M), ranging from 3.5-fold (ciglitazone) to 7.5-fold (rosiglitazone) after 24-h exposure (Fig. 1B) . In contrast, none of the ⌬2 derivatives elicited any significant activation of the reporter.
These resulting ⌬2 analogs (⌬2TG, ⌬2RG, ⌬2PG, and ⌬2CG), through lack of global PPAR activity, exhibited similar antiproliferative potency against prostate cancer cells as their parent compounds . Among them, ⌬2TG and ⌬2CG were active in inducing apoptosis with IC 50 in the range between 15 and 20 M (compared with 20-25 M for troglitazone and ciglitazone) in serum-free medium against various prostate cancer cell lines, whereas ⌬2RG and ⌬2PG exhibited no significant effect on apoptosis even at 50 M . The apoptosis-inducing activity of troglitazone, ciglitazone, and their ⌬2 analogs, however, was attenuated in the presence of serum because of the effects of growth factors on the activation of intracellular signaling and the high serum protein-binding affinity of these agents. As shown in Fig. 2A , no appreciable antiproliferative activity was noted with up to 50 M troglitazone or ⌬2TG in the presence of 10% FBS, whereas these agents were able to elicit significant antitumor effects as low as 10 M in serum-free medium.
From a mechanistic perspective, these PPAR␥-inactive ⌬2 analogs allowed us to discern the role of PPAR␥ activation in various pharmacological effects of thiazolidinediones, including those on Bcl-xL/Bcl-2 inhibition and cyclin D1 repression Shiau et al., 2005) . In this study, we assessed the time-dependent effect of individual thiazolidinediones and their ⌬2 counterparts, 10 M each, on the secretion of PSA in LNCaP cells in 10% FBS-supplemented medium (Fig. 2B) . As shown, DHT (10 nM) stimulated significant accumulations of secretary PSA in the medium by 9-fold throughout the 3-day time course, which could be differentially suppressed by individual thiazolidinediones. Although exposure to troglitazone and ciglitazone for 3 days reduced the PSA secretion by 55% (P Ͻ 0.01), rosiglitazone and pioglitazone, which are more potent PPAR␥ agonists, were only marginally effective. It is noteworthy that the PPAR␥-inactive ⌬2 analogs were more effective than their parental thiazolidinediones, suggesting the dissociation of the effect on PSA down-regulation from PPAR␥ activation. Treatment of LNCaP cells with ⌬2TG or ⌬2CG for 3 days inhibited PSA excretion by as much as 80% (P Ͻ 0.001), whereas ⌬2RG and ⌬2PG attenuated PSA in medium by 50% and 40%, respectively (P Ͻ 0.01). This decrease in PSA secretion was not due to reduced cell viability because these agents at 10 M were not able to induce appreciable apoptotic death in the presence of 10% FBS. Together, these findings suggest that troglitazone and ciglitazone mediated PSA down-regulation through a PPAR␥-independent mechanism. Figure 3A depicts the time-dependent effect of 10 M thiazolidinediones and their ⌬2 analogs on the intracellular protein levels of PSA and AR in LNCaP cells in 10% FBS-supplemented medium. As shown, DHT treatment increased PSA expression in a time-dependent manner, and the effect of individual agents on intracellular PSA production paralleled that of secretary PSA. Troglitazone, ciglitazone, ⌬2TG, and ⌬2CG were effective in reducing PSA expression as early as 24 h after treatment. The effect of troglitazone on repressing PSA expression is reminiscent of that reported in the literature (Hisatake et al., 2000) . In contrast, rosiglitazone, pioglitazone, or their ⌬2 derivatives did not give rise to appreciable reduction in PSA expression. Moreover, the expression level of AR was not altered by any of the test agents at 10 M, suggesting that this PSA down-regulation was not attributable to decreased AR expression.
Nevertheless, it is noteworthy that troglitazone and ⌬2TG at much higher concentrations were capable of lowering AR levels in LNCaP cells, although the underlying mechanism remained unclear. The IC 50 values for suppressing AR expression were approximately 40 and 30 M for troglitazone and ⌬2TG, respectively (Fig. 3B) . Together, these data indicate that the effects of troglitazone and ⌬2TG on the repression of PSA and AR were mediated through distinct mechanisms. LNCaP cells were seeded in T-25 flasks and incubated with 10% charcoal-stripped FBScontaining RPMI 1640 medium for 2 days with or without 10 nM DHT, and exposed to individual tested agents at 10 M, for the indicated times. Equivalent amounts of protein from cell lysates were electrophoresed and probed by Western blotting with individual antibodies. These immunoblots are representative of three independent experiments. B, dose-dependent effect of TG and ⌬2TG on PSA and AR expression in DHTstimulated LNCaP cells after a 48-h treatment. LNCaP cells were treated with the indicated doses of TG or ⌬2TG as aforementioned for 48 h. Equivalent amounts of protein from cell lysates were electrophoresed and probed by Western blotting with individual antibodies. These immunoblots are representative of three independent experiments.
PPAR␥ Agonist-Mediated PSA Down-Regulation 1567
This PSA down-regulation was also confirmed in another androgen-dependent human prostate carcinoma cell line, 22RV1. 22RV1 cells exhibit two aberrant forms of AR (van Bokhoven et al., 2003) and expressed substantially higher levels of PPAR␥ compared with LNCaP cells (Fig. 4A) . Although 22RV1 cells secreted low levels of PSA in the presence of 10 nM DHT, treatment with these agents resulted in a significant suppression of PSA secretion, especially after 48 h (B). As observed in LNCaP cells, intracellular PSA levels in 22RV1 cells were down-regulated by 10 M troglitazone and ⌬2TG in a time-dependent manner, whereas AR expression was unaffected (C).
Troglitazone and ⌬2TG Do Not Affect Nuclear Translocation of AR. Pharmacological agents might interfere with PSA expression at different stages of AR-mediated PSA transactivation, including AR expression, ligand binding, AR dimerization, and nuclear translocation, and AR binding to the androgen response elements (AREs). To discern these possibilities, we carried out immunocytochemical analysis to envisage the cellular distribution of AR in LNCaP cells treated with 10 M troglitazone or ⌬2TG. Figure 5 demonstrates that DHT treatment facilitated the translocation of AR from the cytoplasm to the nucleus. Exposure to 10 M troglitazone or ⌬2TG had no effect on this DHT-mediated AR translocation, and the total AR-staining intensity was not affected. This finding suggested that the down-regulation occurred at the level of ARE transactivation.
Troglitazone and ⌬2TG Block Androgen Activation of the AREs in the PSA Promoter. To analyze the effect of troglitazone and ⌬2TG on DHT-mediated transactivation of the PSA promoter, we transfected LNCaP cells with the PSA6.0-Luc vector, a luciferase reporter linked with the 6.0- Immunocytochemical evidence that troglitazone (TG) and ⌬2TG at 10 M do not interfere with DHT-stimulated nuclear localization of AR in LNCaP cells. LNCaP cells were exposed to individual treatments in 10% charcoal-stripped FBS-supplemented phenol red-free RPMI 1640 medium for 48 h, and immunocytochemistry was performed as described under Materials and Methods. As shown, DHT facilitated the nuclear localization of AR, which was not interfered by 10 M TG or ⌬2TG. kilobase PSA promoter (Zhang et al., 2002) . DHT increased the reporter activity in a dose-dependent manner, and both troglitazone and ⌬2TG at 10 M could significantly suppress the luciferase activity (P Ͻ 0.001) (Fig. 6A) . For example, in the presence of 10 nM DHT, the extent of inhibition by troglitazone and ⌬2TG was 52 and 60%, respectively. To confirm this was an AR-dependent effect, LNCaP cells were cotransfected with the PSA6.0-Luc vector and a human AR expression construct (pCMVhAR), resulting in increase in AR expression by 2.2-fold (Fig. 6B) . Expression of ectopic AR not only increased the basal activity of luciferase but could also rescue the suppressing effect of 10 M troglitazone and ⌬2TG on DHT-induced increase of luciferase activity in PSA6.0-Luc-transfected LNCaP cells (Fig. 6C) .
To assess how troglitazone and ⌬2TG affected AR-mediated transactivation of the PSA promoter, ChIP assays were performed to detect the binding of AR to ARE I and ARE II in the promoter region. LNCaP cells were cultured in phenol red-free RPMI 1640 medium containing 10% charcoal-dextran-stripped FBS for 2 days, followed by exposure to 10 nM DHT in the absence of presence of 10 M troglitazone or ⌬2TG for 12 h. After formaldehyde treatment of cells, AR antibodies were used to immunoprecipitate AR-bound genomic DNA fragments, followed by PCR analysis of the genomic DNA using pairs of primers spanning the AREs according to a published procedure (Shang et al., 2002) . As shown in Fig. 7 , treatment of cells with 10 nM DHT increased AR recruitment to both AREI and AREII. This DHT-induced AR recruitment was specific because no AR binding was noted to the middle control region within the PSA promoter; AR binding was not noted in the negative control in which anti-IgG was used for immunoprecipitation. Troglitazone and ⌬2TG diminished the DHT-induced AR binding to AREI by 34 and 47%, respectively, and caused approximately 16 and 45% reduction, respectively, in the AR binding to AREII.
Discussion
This study assessed the mechanism by which thiazolidinediones mediated the inhibition of PSA secretion in androgen-dependent prostate cancer cells. Two lines of evidence indicate that the effect of thiazolidinediones on PSA downregulation was independent of PPAR␥ activation. First, this thiazolidinedione-mediated PSA down-regulation was structure-specific irrespective of the relative potency in PPAR␥ activation. For example, while 10 M troglitazone and ciglitazone were active, the more potent PPAR␥ agonists rosiglitazone and pioglitazone at the same concentration were not. Second, ⌬2TG and ⌬2CG, although devoid of PPAR␥ activity, exhibited higher potency than their parent molecules in suppressing PSA secretion.
Although PSA secretion was significantly inhibited by 10 M troglitazone and ⌬2TG in both LNCaP and 22RV1 cells, no appreciable changes in AR levels were noted even after 72-h exposure, refuting a possible link between PSA downregulation and decrease in AR expression. This finding indicates that the mode of troglitazone-and ⌬2TG-mediated PSA repression was different from that of vitamin E succinate (Zhang et al., 2002) , even thought these molecules share the chroman substructure. Vitamin E succinate mediated PSA repression by inhibiting AR expression, whereas troglitazone and ⌬2TG at 10 M exhibited no appreciable effect on AR expression. In addition, the finding that ciglitazone and ⌬2CG could also cause the down-regulation of PSA secretion argues against the involvement of the chroman moiety in mediating the PSA repressing effect of troglitazone. Moreover, immunocytochemical analysis demonstrates that these agents did not interfere with the DHT-stimulated nuclear translocation of AR. However, reporter gene and ChIP assays revealed that troglitazone and ⌬2TG inhibited AR recruitment to the AREI and AREII within the PSA Fig. 7 . ChIP analysis of the inhibitory effect of troglitazone (TG) and ⌬2TG on DHT-stimulated AR recruitment to the AREI and AREII within the PSA promoter region. A, LNCaP cells were exposed to 10 nM DHT alone or the combination of 10 nM DHT and 10 M TG or ⌬2TG for 12 h. The drug-treated cells were collected, cross-linked, and sonicated, and soluble chromatin was prepared as described under Materials and Methods. Left, size of the genomic DNA fragments from solubilized chromatin. Right, ChIP was performed by using antibodies against AR or IgG, and PCR was conducted by using primers designed to detect the AREI binding site, the AREII binding site, and an irrelevant region within the actin promoter region (middle), as described under Materials and Methods. B, columns, mean of the relative AR binding, normalized to input; bars, S.D. (n ϭ 3). Is the ability of oral troglitazone to reduce serum PSA levels in prostate cancer patients is therapeutically relevant? A major concern is that the concentration for troglitazone to mediate antitumor effects in prostate cancer cells is severalfold higher than that of PSA down-regulation, which is difficult to attain at therapeutic doses. For example, in the presence of 5 to 10% serum, neither troglitazone nor ciglitazone exhibited antiproliferative activity until the concentrations reached more than 50 M. Therefore, decrease in serum PSA levels in response to troglitazone treatment might not truly reflect the growth status of the prostate tumor in patients.
Nevertheless, it is noteworthy that troglitazone and ⌬2TG at doses higher than 30 M were able to inhibit AR expression. Moreover, troglitazone at a very high dose (i.e., 500 mg/kg/day) has been shown to be effective in suppressing PC-3 xenograft growth in nude mice (Kubota et al., 1998) . From a translational perspective, separation of these two pharmacological activities, PPAR␥ activation versus AR down-regulation, provides a molecular basis to use ⌬2TG as a molecular platform to design AR-ablative agents. In light of the important role of AR in prostate tumorigenesis, these AR-ablative agents have the translational relevance to be developed into antitumor agents for the prevention and/or therapy of prostate cancer, which constitutes the focus of this investigation.
